VNRX / VolitionRx announces pricing of underwritten public offering of 3 million shares at a public offering price of $2.00 each

VolitionRx (NYSE-A:VNRX) has highlighted a recently published paper in Annals of Intensive Care which shows the company's Nu.Q NETs test is a promisin more_horizontal

VolitionRx (NYSE-A:VNRX), the multinational epigenetics company, said it was “delighted” to host Ambassador Michael Adler, the US Ambassador to th more_horizontal

VolitionRx (NYSE-A:VNRX) said it will be presenting three scientific abstracts about cancer detection tools at the annual congress of the European Soc more_horizontal

VolitionRx (NYSE-A:VNRX) has revealed insights from a recent Key Opinion Leader (KOL) roundtable focused on sepsis management. The KOL roundtable brou more_horizontal

VolitionRx (NYSE-A:VNRX) Limited has announced that it is participating in a webinar hosted by Edison Group, to expound new cancer data to be presente more_horizontal

VolitionRx (NYSE-A:VNRX) said it is hosting a roundtable discussion in Athens this weekend which will bring together world-renowned experts in sepsis, more_horizontal

VolitionRx Limited (NYSE:VNRX ) Q2 2023 Results Conference Call August 15, 2023 8:30 AM ET Company Participants Scott Powell - Executive Vice Presiden more_horizontal

VolitionRx (NYSE-A:VNRX) Limited announced the pricing of an underwritten public offering with expected gross proceeds of $16.5 million. The epigeneti more_horizontal